Amarantus BioSciences Announces Partnership Agreement With Generex Biotechnology

Marketwire (Jun 1 2011) Life Sciences

1. Amarantus BioSciences, Inc. ("Amarantus"), a biotechnology company developing first-in-class, disease-modifying treatments that address an underlying cause of cell death known as apoptosis, today announced a licensing agreement under which Amarantus will in-license Generex Biotechnology, Inc.'s ("Generex") drug delivery technologies in all therapeutic areas, excluding diabetes mellitus, where Generex and Amarantus will pursue a joint research collaboration. (Read Full Article)

   Bookmark or Share this article

Login to comment.